-
For CF Treatment, FDA Grants Priority Review to Vertex’s Triple Combo
The FDA has granted priority review to Vertex’s new drug application for its first triple combination — elexacaftor, tezacaftor, and ivacaftor — for cystic fibrosis. Learn more here.
What are your thoughts about this news?
Sorry, there were no replies found.
Log in to reply.